In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y.
| Image |  |
|---|---|
| Description | scientific article published in October 2016 |
| Author/s |
author: Gregory Lip |
| Publication date | October 1, 2016 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |